<p>Arcus Biosciences（纽约证券交易所代码：RCUS - 获取免费报告）在一份周五发布给客户和投资者的研究报告中，银行美林的股票研究人员将其目标价从 17.00 美元上调至 26.00 美元，Benzinga 报道。该券商目前对该股票给予 “中性” 评级。银行美林的目标价意味着该股票相较于之前收盘价有 0.68% 的潜在上涨空间。</p>
<ul>
<li>从落后者到领军者：小型股正在崛起</li>
</ul>
<p>其他研究分析师最近也对该股票发布了研究报告。Weiss Ratings 在 10 月 8 日的报告中重申了对 Arcus Biosciences 股票的 “卖出（d-）” 评级。HC Wainwright 在 10 月 29 日的研究报告中将 Arcus Biosciences 的目标价从 24.00 美元上调至 28.00 美元，并给予该公司 “买入” 评级。高盛集团在 10 月 30 日的研究报告中将 Arcus Biosciences 的目标价从 14.00 美元上调至 16.00 美元，并给予该公司 “中性” 评级。Truist Financial 在 10 月 7 日的报告中重新发布了 “买入” 评级，并将 Arcus Biosciences 的目标价从 32.00 美元上调至 39.00 美元。最后，富国银行在 10 月 20 日的报告中将 Arcus Biosciences 的目标价从 25.00 美元上调至 29.00 美元，并给予该股票 “超配” 评级。七位投资分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Arcus Biosciences 的共识评级为 “适度买入”，共识目标价为 29.44 美元。</p>
<p>获取 <strong>Arcus Biosciences</strong> 的提醒：</p>
<p><strong>获取我们对 RCUS 的最新分析</strong></p>
<h2>Arcus Biosciences 股票表现</h2>
<ul>
<li>MarketBeat 周回顾 – 7/10 - 7/14</li>
</ul>
<p>在周五的交易中，纽约证券交易所 RCUS 的股票上涨了 0.27 美元，达到了 25.83 美元。该股票的交易量为 362,857 股，而其平均交易量为 1,121,739 股。该公司的债务与股本比率为 0.22，流动比率为 3.65，速动比率为 3.65。该股票的市值为 27.9 亿美元，市盈率为-7.50，贝塔值为 0.90。Arcus Biosciences 的 52 周低点为 6.50 美元，52 周高点为 26.32 美元。该公司的 50 日移动平均线为 17.67 美元，200 日移动平均线为 12.43 美元。</p>
<p>Arcus Biosciences（纽约证券交易所代码：RCUS - 获取免费报告）最近在 10 月 28 日发布了季度财报。该公司报告本季度每股收益为（1.27 美元），超出市场共识预期的（1.33 美元）0.06 美元。该业务本季度的收入为 2600 万美元，而市场共识预期为 1989 万美元。Arcus Biosciences 的净利润率为-136.40%，股本回报率为-68.17%。与去年同期相比，该公司的收入下降了 45.8%。在去年同期，该公司每股收益为（1.00 美元）。分析师预测 Arcus Biosciences 在本财年的每股收益将为-3.15 美元。</p>
<h2>内部活动</h2>
<ul>
<li>吉利德通过投资 AlloVir 和 Arcus 扩大生物技术足迹</li>
</ul>
<p>在其他新闻中，首席财务官 Robert C. Goeltz II 在 10 月 28 日的交易中出售了 5000 股 Arcus Biosciences 的股票。股票以平均价格 20.00 美元出售，总交易额为 100,000.00 美元。交易完成后，首席财务官直接持有该公司 92,138 股股票，价值约为 1,842,760 美元。此交易代表其持股比例减少了 5.15%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。此外，首席会计官 Alexander Azoy 在 9 月 29 日的交易中出售了 2831 股该公司的股票。股票以平均价格 13.00 美元出售，总价值为 36,803.00 美元。交易完成后，首席会计官直接持有该公司 27,363 股股票，价值约为 355,719 美元。此交易代表其持股比例减少了 9.38%。该销售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士共出售了 210,875 股公司股票，价值 4,017,263 美元。当前 9.60% 的股票由公司内部人士持有。</p>
<h2>对 Arcus Biosciences 的对冲基金看法</h2>
<p>对冲基金和其他机构投资者最近增加或减少了对该公司的持股。GAMMA Investing LLC 在第三季度将其在 Arcus Biosciences 的持股增加了 59.1%。GAMMA Investing LLC 现在拥有该公司 2,748 股股票，价值 37,000 美元，此前在该期间内又购买了 1,021 股。SBI Securities Co. Ltd.在第三季度将其在 Arcus Biosciences 的持股增加了 13,547.6%。SBI Securities Co. Ltd.现在拥有该公司 2,866 股股票，价值 39,000 美元，此前在上个季度又购买了 2,845 股。CWM LLC 在第二季度将其在 Arcus Biosciences 的持股增加了 233.6%。CWM LLC 现在拥有该公司 5,441 股股票，价值 44,000 美元，此前在该期间内又购买了 3,810 股。Ameritas Investment Partners Inc.在第二季度将其在 Arcus Biosciences 的持股增加了 34.3%。Ameritas Investment Partners Inc.现在拥有该公司 7,038 股股票，价值 57,000 美元，此前在上个季度又购买了 1,796 股。最后，PNC Financial Services Group Inc.在第二季度将其在 Arcus Biosciences 的持股增加了 440.3%。PNC Financial Services Group Inc.现在拥有该公司 7,597 股股票，价值 62,000 美元，此前在上个季度又购买了 6,191 股。92.89% 的股票由机构投资者持有。</p>
<h2>关于 Arcus Biosciences</h2>
<p>（获取免费报告）</p>
<p>Arcus Biosciences, Inc.是一家临床阶段的生物制药公司，专注于在美国开发和商业化癌症疗法。该公司的产品管线包括 Domvanalimab，一种抗 TIGIT 抗体，目前正在进行第二期和第三期临床试验；以及 AB308，一种正在研究的抗 TIGIT 单克隆抗体，目前处于 1b 期临床试验，旨在研究晚期实体瘤和血液恶性肿瘤患者。</p>
<h2>另见</h2>
<ul>
<li>五只我们认为比 Arcus Biosciences 更好的股票</li>
<li>如何寻找被低估的股票</li>
<li>加仓 Fiserv 的两个理由，远离它的一个理由</li>
<li>技术股解析：关于科技你需要知道的</li>
<li>购买三只股票以迎接 AI 基础设施的演变</li>
<li>恒生指数是什么？</li>
<li>Semtech 的数据中心芯片如何推动 AI 热潮</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJDVVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJDVVM"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Arcus Biosciences 吗？</h2>
<p>在考虑 Arcus Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Arcus Biosciences 并不在名单上。</p>
<p>尽管 Arcus Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RCUS

<p>美国银行将 Arcus Biosciences 的目标价格从 17.00 美元上调至 26.00 美元，表示潜在上涨幅度为 0.68%。该股票的共识评级为 “适度买入”，目标价格为 29.44 美元。近期注意到内部人士的销售和对冲基金活动，内部人士持有该股票的 9.60%</p>

<p>Arcus Biosciences (NYSE:RCUS - Get Free Report) had its price target hoisted by equities researchers at Bank of America from $17.00 to $26.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a &#34;neutral&#34; rating on the stock. Bank of America's target price would indicate a potential upside of 0.68% from the stock's previous close.</p>
<div class="lb-trans"><p>Arcus Biosciences（纽约证券交易所代码：RCUS - 获取免费报告）在一份周五发布给客户和投资者的研究报告中，银行美林的股票研究人员将其目标价从 17.00 美元上调至 26.00 美元，Benzinga 报道。该券商目前对该股票给予 “中性” 评级。银行美林的目标价意味着该股票相较于之前收盘价有 0.68% 的潜在上涨空间。</p>
</div><ul>
<li>From laggards to leaders: Small caps on the rise</li>
</ul>
<div class="lb-trans"><ul>
<li>从落后者到领军者：小型股正在崛起</li>
</ul>
</div><p>Other research analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. HC Wainwright lifted their price target on Arcus Biosciences from $24.00 to $28.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, October 29th. The Goldman Sachs Group raised their target price on shares of Arcus Biosciences from $14.00 to $16.00 and gave the company a &#34;neutral&#34; rating in a research note on Thursday, October 30th. Truist Financial reissued a &#34;buy&#34; rating and issued a $39.00 price target (up previously from $32.00) on shares of Arcus Biosciences in a report on Tuesday, October 7th. Finally, Wells Fargo &amp; Company lifted their price objective on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an &#34;overweight&#34; rating in a report on Monday, October 20th. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Arcus Biosciences has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $29.44.</p>
<div class="lb-trans"><p>其他研究分析师最近也对该股票发布了研究报告。Weiss Ratings 在 10 月 8 日的报告中重申了对 Arcus Biosciences 股票的 “卖出（d-）” 评级。HC Wainwright 在 10 月 29 日的研究报告中将 Arcus Biosciences 的目标价从 24.00 美元上调至 28.00 美元，并给予该公司 “买入” 评级。高盛集团在 10 月 30 日的研究报告中将 Arcus Biosciences 的目标价从 14.00 美元上调至 16.00 美元，并给予该公司 “中性” 评级。Truist Financial 在 10 月 7 日的报告中重新发布了 “买入” 评级，并将 Arcus Biosciences 的目标价从 32.00 美元上调至 39.00 美元。最后，富国银行在 10 月 20 日的报告中将 Arcus Biosciences 的目标价从 25.00 美元上调至 29.00 美元，并给予该股票 “超配” 评级。七位投资分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Arcus Biosciences 的共识评级为 “适度买入”，共识目标价为 29.44 美元。</p>
</div><p>Get <strong>Arcus Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Arcus Biosciences</strong> 的提醒：</p>
</div><p><strong>Get Our Latest Analysis on RCUS</strong></p>
<div class="lb-trans"><p><strong>获取我们对 RCUS 的最新分析</strong></p>
</div><h2>Arcus Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>Arcus Biosciences 股票表现</h2>
</div><ul>
<li>MarketBeat Week in Review – 7/10 - 7/14</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 7/10 - 7/14</li>
</ul>
</div><p>Shares of NYSE RCUS traded up $0.27 during trading on Friday, reaching $25.83. 362,857 shares of the stock traded hands, compared to its average volume of 1,121,739. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65. The stock has a market capitalization of $2.79 billion, a P/E ratio of -7.50 and a beta of 0.90. Arcus Biosciences has a 52-week low of $6.50 and a 52-week high of $26.32. The company has a 50-day moving average of $17.67 and a 200-day moving average of $12.43.</p>
<div class="lb-trans"><p>在周五的交易中，纽约证券交易所 RCUS 的股票上涨了 0.27 美元，达到了 25.83 美元。该股票的交易量为 362,857 股，而其平均交易量为 1,121,739 股。该公司的债务与股本比率为 0.22，流动比率为 3.65，速动比率为 3.65。该股票的市值为 27.9 亿美元，市盈率为-7.50，贝塔值为 0.90。Arcus Biosciences 的 52 周低点为 6.50 美元，52 周高点为 26.32 美元。该公司的 50 日移动平均线为 17.67 美元，200 日移动平均线为 12.43 美元。</p>
</div><p>Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, beating the consensus estimate of ($1.33) by $0.06. The business had revenue of $26.00 million for the quarter, compared to the consensus estimate of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The company's revenue was down 45.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.00) earnings per share. Analysts forecast that Arcus Biosciences will post -3.15 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Arcus Biosciences（纽约证券交易所代码：RCUS - 获取免费报告）最近在 10 月 28 日发布了季度财报。该公司报告本季度每股收益为（1.27 美元），超出市场共识预期的（1.33 美元）0.06 美元。该业务本季度的收入为 2600 万美元，而市场共识预期为 1989 万美元。Arcus Biosciences 的净利润率为-136.40%，股本回报率为-68.17%。与去年同期相比，该公司的收入下降了 45.8%。在去年同期，该公司每股收益为（1.00 美元）。分析师预测 Arcus Biosciences 在本财年的每股收益将为-3.15 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><ul>
<li>Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus</li>
</ul>
<div class="lb-trans"><ul>
<li>吉利德通过投资 AlloVir 和 Arcus 扩大生物技术足迹</li>
</ul>
</div><p>In other news, CFO Robert C. Goeltz II sold 5,000 shares of Arcus Biosciences stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the completion of the transaction, the chief financial officer directly owned 92,138 shares in the company, valued at approximately $1,842,760. This trade represents a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, CAO Alexander Azoy sold 2,831 shares of the firm's stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $13.00, for a total value of $36,803.00. Following the transaction, the chief accounting officer directly owned 27,363 shares of the company's stock, valued at approximately $355,719. This trade represents a 9.38% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 210,875 shares of company stock worth $4,017,263. 9.60% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席财务官 Robert C. Goeltz II 在 10 月 28 日的交易中出售了 5000 股 Arcus Biosciences 的股票。股票以平均价格 20.00 美元出售，总交易额为 100,000.00 美元。交易完成后，首席财务官直接持有该公司 92,138 股股票，价值约为 1,842,760 美元。此交易代表其持股比例减少了 5.15%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。此外，首席会计官 Alexander Azoy 在 9 月 29 日的交易中出售了 2831 股该公司的股票。股票以平均价格 13.00 美元出售，总价值为 36,803.00 美元。交易完成后，首席会计官直接持有该公司 27,363 股股票，价值约为 355,719 美元。此交易代表其持股比例减少了 9.38%。该销售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士共出售了 210,875 股公司股票，价值 4,017,263 美元。当前 9.60% 的股票由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Arcus Biosciences</h2>
<div class="lb-trans"><h2>对 Arcus Biosciences 的对冲基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its stake in shares of Arcus Biosciences by 59.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company's stock worth $37,000 after purchasing an additional 1,021 shares during the period. SBI Securities Co. Ltd. grew its position in shares of Arcus Biosciences by 13,547.6% during the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company's stock worth $39,000 after purchasing an additional 2,845 shares in the last quarter. CWM LLC raised its stake in Arcus Biosciences by 233.6% during the 2nd quarter. CWM LLC now owns 5,441 shares of the company's stock valued at $44,000 after purchasing an additional 3,810 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in Arcus Biosciences by 34.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company's stock worth $57,000 after purchasing an additional 1,796 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in Arcus Biosciences by 440.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company's stock valued at $62,000 after buying an additional 6,191 shares in the last quarter. 92.89% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近增加或减少了对该公司的持股。GAMMA Investing LLC 在第三季度将其在 Arcus Biosciences 的持股增加了 59.1%。GAMMA Investing LLC 现在拥有该公司 2,748 股股票，价值 37,000 美元，此前在该期间内又购买了 1,021 股。SBI Securities Co. Ltd.在第三季度将其在 Arcus Biosciences 的持股增加了 13,547.6%。SBI Securities Co. Ltd.现在拥有该公司 2,866 股股票，价值 39,000 美元，此前在上个季度又购买了 2,845 股。CWM LLC 在第二季度将其在 Arcus Biosciences 的持股增加了 233.6%。CWM LLC 现在拥有该公司 5,441 股股票，价值 44,000 美元，此前在该期间内又购买了 3,810 股。Ameritas Investment Partners Inc.在第二季度将其在 Arcus Biosciences 的持股增加了 34.3%。Ameritas Investment Partners Inc.现在拥有该公司 7,038 股股票，价值 57,000 美元，此前在上个季度又购买了 1,796 股。最后，PNC Financial Services Group Inc.在第二季度将其在 Arcus Biosciences 的持股增加了 440.3%。PNC Financial Services Group Inc.现在拥有该公司 7,597 股股票，价值 62,000 美元，此前在上个季度又购买了 6,191 股。92.89% 的股票由机构投资者持有。</p>
</div><h2>About Arcus Biosciences</h2>
<div class="lb-trans"><h2>关于 Arcus Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.</p>
<div class="lb-trans"><p>Arcus Biosciences, Inc.是一家临床阶段的生物制药公司，专注于在美国开发和商业化癌症疗法。该公司的产品管线包括 Domvanalimab，一种抗 TIGIT 抗体，目前正在进行第二期和第三期临床试验；以及 AB308，一种正在研究的抗 TIGIT 单克隆抗体，目前处于 1b 期临床试验，旨在研究晚期实体瘤和血液恶性肿瘤患者。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Arcus Biosciences</li>
<li>How to Find Undervalued Stocks</li>
<li>2 Reasons to Load Up on Fiserv, 1 to Stay Away</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>3 Stocks to Buy for the Evolution of AI Infrastructure</li>
<li>What is the Hang Seng index?</li>
<li>How Semtech’s Data Center Chips Are Powering the AI Boom</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Arcus Biosciences 更好的股票</li>
<li>如何寻找被低估的股票</li>
<li>加仓 Fiserv 的两个理由，远离它的一个理由</li>
<li>技术股解析：关于科技你需要知道的</li>
<li>购买三只股票以迎接 AI 基础设施的演变</li>
<li>恒生指数是什么？</li>
<li>Semtech 的数据中心芯片如何推动 AI 热潮</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJDVVM" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=RCUS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Arcus Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Arcus Biosciences 吗？</h2>
</div><p>Before you consider Arcus Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Arcus Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Arcus Biosciences 并不在名单上。</p>
</div><p>While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Arcus Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

美国银行的分析师表示，Arcus Biosciences（NYSE:RCUS）的股价预计将会上涨